The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
Official Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-naïve Patients With MCD Subtype DLBCL
Study ID: NCT05234684
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naïve patients with MCD subtype DLBCL.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
Anhui Provincal Cancer Hospital, Hefei, Anhui, China
Beijing Hospital, Beijing, Beijing, China
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
The Southwest Hospital of AMU, Chongqing, Chongqing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
The First Affiliated Hospital Of XIAMEN University, Xiamen, Fujian, China
Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
The First People's Hospital of Foshan, Foshan, Guangdong, China
Guangdong General Hospital, Guangzhou, Guangdong, China
ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
PEKING University SHENZHEN Hospital, Shenzhen, Guangdong, China
Sun Yat-sen University Cancer Center Internal medicine department, Guandong, Guangzhou, China
Affiliated Hospital of Hebei University, Baoding, Hebei, China
The Second Hospital of Hebei Medical University, Shijia Zhuang, Hebei, China
The First Affiliated Hospital of Henan University of science and Technology, Luoyang, Henan, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Hunan Cancer Hospital, Changsha, Hunan, China
Chenzhou first people's Hospital, Chenzhou, Hunan, China
The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Wuxi People's Hospital, Wuxi, Jiangsu, China
Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China
The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
The First Hospital of China Medical University, Shenyang, Liaoning, China
Qilu Hospital Of Shandong University, Jinan, Shandong, China
Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Shanghai 6th People's Hospital, Shanghai, Shanghai, China
The first Affiliated Hospital Of Xi'an Jiaotong University, Xi'an, Shanxi, China
The Second Affiliated Hospital Of Xi'an Jiaotong University, Xi'an, Shanxi, China
West China Hospital Sichuan University, Chengdu, Sichuan, China
Tianjin Cancer Hospital, Tianjin, Tianjin, China
Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
The first affiliated Hospital Zhejiang University School Of Medicine, Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital Zhejiang University School Of Medicine, Hangzhou, Zhejiang, China
Shaoxing People's Hospital, Shaoxing, Zhejiang, China
Name: Weili Zhao
Affiliation: Ruijin Hospital
Role: PRINCIPAL_INVESTIGATOR